The generics manufacturer Olon and enzyme product developer Zymvol have announced a strategic collaboration designed to accelerate the adoption of biocatalysis by pharma manufacturers.
The partnership will combine Zymvol's AI-powered enzyme design with Olon's capabilities for large-scale biomanufacturing, creating a complete pathway from enzyme discovery to production at ton-scale.
The companies announced that their collaboration will address cost, timeline and scale-up challenges that have hindered the widespread industrial adoption of biocatalysis, positioning the technology as a practical, scalable manufacturing solution for the pharmaceutical industry.
Enzyme-enabled manufacturing routes offer a compelling pathway to lower costs, improved sustainability and more resilient supply chains.
The collaboration between Olon and Zymvol leverages the potential of advanced computational enzyme design alongside expertise in large-scale fermentation, process development and manufacturing.
Why this matters
The collaboration aims to address a critical component in today's market: speed.
Speaking to Manufacturing Chemist, Dr Ester Masllorens, SVP Global R&D at Olon, said that the integration of Zymvol's enzyme design technology into Olon's already proven biomanufacturing infrastructure would position the company as a leader in the space and addresses the growing demands for efficiency, sustainability and supply chain resilience.
This is a small extract of the full article which is available
ONLY to premium content subscribers.
Click below to get premium content on Manufacturing Chemist.
Not yet a Subscriber?